Inspira Technologies Announces Positive Data From AI-powered HYLA Blood Sensor Study

(RTTNews) - Inspira Technologies Oxy B.H.N. Ltd. (IINN), Tuesday announced that the company has announced positive results from the clinical study of its AI-powered HYLA blood sensor, which is designed to monitor blood parameters.

During the study, the HYLA achieved 96 percent accuracy for a key parameter, as compared to traditional blood test analyzers. Also, it demonstrated 92.3 percent accuracy for identifying oxygen deficiencies.

The company noted that the accurate and real-time continuous measurement capability of HYLA might help prevent blood oxygen deficiency during surgical procedures without the need for blood draws.

The company expects the new results to support the advancement towards its expected Food and Drug Administration submission of the first HYLA configuration in the second half of 2025.

Upon receiving the FDA clearance, the company plans to deploy this core technology of the INSPIRA ART in U.S. hospitals for data collection and post-market validation.

In the pre-market hours, Inspira's stock is trading at $0.84, down 2.9 percent on the Nasdaq.